Furthermore, most patients had ER (71%) and PgR (58.5%) positive status, high MIB1 (57.9%) and HER2/neu negative (50.6%); 10.4% were triple negative breast cancers. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.